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and distribution of oral artemisinin
monotherapy in Myanmar: evidence from a
nationally representative outlet survey
ACTwatch Group1*, Si Thu Thein2*, Hnin Su Su Khin2 and Aung Thi3
Abstract
Background: The containment of artemisinin resistance in Myanmar, historically an important probable origin and
route of anti-malarial resistance to the India sub-continent and beyond, is crucial to global malaria control and elimination. This paper describes what is currently known about the sale and distribution of oral artemisinin monotherapy
(AMT) across Myanmar, where this medicine is commonly found.
Methods: A nationally representative 2015 outlet survey was conducted in the private sector, and among community health workers across four geographical domains. A national sample of outlets was screened for availability of
malaria testing and treatment, and an audit was completed for all anti-malarials.
Results: A total of 3859 outlets across Myanmar had an anti-malarial in stock on the day of survey. Of the 3859
anti-malarial stocking outlets, 988 outlets stocked oral AMT. Availability of oral AMT was highest among outlets in the
Western border (36.8%) versus other domains (Eastern, 15.0%; Central, 19.3% Coastal, 10.7%). Over 90% of the oral
AMT service delivery points were private sector outlets: general retailers (49.4%), pharmacies (23.5%), and itinerant drug vendors (14.2%). Eleven unique oral AMT products were audited. The most common product audited was
Artesunate®, manufactured by Mediplantex in Vietnam, which accounted for 79.9% of the oral AMT market share.
Other oral AMT products were manufactured in China and in Myanmar. Over 60% of oral AMT products had a shelf
life at purchase of greater than 2 years and only 14.7% were expired. The median number of oral AMT tablets typically dispensed to treat malaria was two tablets, approximately one tenth of a full adult course. The median price of a
50 mg tablet was $0.16.
Conclusions: Given the high availability and distribution of oral AMT, it is possible that Myanmar has become the last
remaining viable market for any oral AMT in the region for manufacturers. National and international organizations
need to act quickly and effectively to stop the production and distribution to both improve malaria control within
Myanmar and reduce risk of artemisinin resistance spreading to India and Africa.
Background
While the World Health Organization (WHO) recommends the use of intravenous and intramuscular artemisinins for treatment of severe malaria [1], the use of
*Correspondence: mlittrell@psi.org; info@actwatch.info;
stthein@psimyanmar.org
1
Population Services International, 1120 19th St NW Suite 600,
Washington, DC 20036, USA2 Population Services International Myanmar,
No. 16, West Shwe Gone Dine 4th Street, Yangon, Myanmar
Full list of author information is available at the end of the article

oral artemisinin-based monotherapies (AMT) is not
recommended for any form of malaria treatment. Oral
AMT is considered to be a major contributing factor to
the development of malaria parasite resistance to artemisinin derivatives [2]. Since 2007, the WHO has urged
regulatory authorities in malaria-endemic countries to
take measures to halt the production and marketing of
these oral monotherapies, and promote access to qualityassured artemisinin-based combination therapies [3].
While many countries have adopted and enforced this
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resolution, the global manufacturing and production
of oral AMT continues [4]. In fact, recent market intelligence data, generated by the ACTwatch project [5, 6],
illustrates that oral AMT continues to be distributed
and sold in some countries, particularly in the private
sector. Findings from the project point to the persistent
widespread availability and distribution of oral AMT
in Myanmar, which accounts for the highest burden of
malaria in the Greater Mekong Sub-region (GMS) and
is notably considered an important probable origin and
route of multi-drug resistance.
Oral artemisinin monotherapy was banned in Myanmar in 2012 by the Myanmar Food and Drug Administration (FDA). However, the regulatory policy permits oral
AMT distributors with a valid 5-year import registration
license awarded prior to the ban to continue to procure
and sell this monotherapy within the country [7]. Given
that oral AMT has a shelf life of 4 years from the time
of manufacture, oral AMT medicines can be produced
and imported until 2017 and could remain on the shelf
until 2021. Indeed, outlet survey trend data from Eastern Myanmar over the years have shown that despite a
plethora of strategies to remove this from the market,
oral artemisinin monotherapy commonly persists [7].
This has included the Artemisinin Monotherapy Replacement (AMTR) project, which was designed to rapidly
remove artemisinin monotherapies from the market by
increasing private sector access to first-line subsidized
artemisinin-based combination therapy (ACT) medicines. Additional project activities targeted private sector providers (general retailers, pharmacies and itinerant
drug vendors) located in Eastern Myanmar to encourage
adoption of ACT.
In 2015, the ACTwatch project for the first time,
implemented a national level outlet survey in Myanmar
across four geographically diverse domains to provide
a complete picture of the availability and distribution
of anti-malarials in the private sector and among community health workers in the not-for profit sector. The
objective of this paper is to provide timely, actionable
evidence to inform urgently needed strategies to remove
oral AMT from Myanmar’s marketplace. This paper
describes what is currently known about the sale and distribution of oral artemisinin monotherapy and answers
several questions, including (1) Where is artemisinin
monotherapy available and distributed? (2) What types
of products are available and distributed? (3) What are
the provider practices regarding the re-supply and sale
of oral artemisinin monotherapy? Evidence from the oral
AMT market will point to recommendations for removing this medicine completely from the market in order
to protect the efficacy of artemisinins in Myanmar and
beyond.
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Methods
All outlets with the potential to sell or distribute antimalarials and/or provide malaria blood testing were
included in the sample. In Myanmar, these included community health workers, private for-profit health facilities, pharmacies, general retail outlets, and itinerant drug
vendors (see Additional file 1). The study was not able to
gain access to government health facilities, namely public
health facilities, and thus were excluded from the study.
The survey was conducted across four study domains:
Eastern (where the AMTR project was implemented),
Central, Western and Coastal areas of the country. A representative sample of clusters (defined as wards in urban
areas and village tracts in rural areas) were selected in
each domain, using probability proportional to population size (PPS). Between 180 and 240 urban wards and
rural tracts in total were selected per domain. Within
each selected ward/village tract, a census of all outlets
with the potential to sell or distribute anti-malarials and/
or provide malaria blood testing was conducted. Outlets
were eligible for a provider interview and a malaria product audit if they met at least one of three study criteria:
(1) one or more anti-malarials reportedly in stock the
day of the survey; (2) one or more anti-malarials reportedly in stock within the 3 months preceding the survey;
and/or (3) provides malaria blood testing (microscopy or
rapid diagnostic test [RDT]) at the time of the survey.
Outlets that met the screening criteria were invited
to participate in the survey, and among providers that
gave verbal informed consent, an audit of all available
anti-malarial medicines and RDT was conducted. Antimalarial audit information included formulation, package size, brand name, active ingredients and strengths,
manufacturer, country of manufacture, reported sale/distribution in the week preceding the survey, retail price,
and wholesale price. Where oral artemisinin monotherapy was found, an additional module was administered
to understand the supply chain for this monotherapy.
Questions included where the medicine was purchased,
when the medicine was last purchased from the supplier,
how many packages were purchased, wholesale price, the
number of tablets typically dispensed, how many packages were currently in stock, and expiry dates for packages in stock. For all interviews a structured, paper-based
questionnaire was administered. Data collection was
implemented from August 18th, 2015 through January
4th, 2016. Interviewer training consisted of standardized
classroom presentations and exercises as well as a field
exercise. Exams administered during training were used
to select data collectors, supervisors, and quality-controllers. Additional training was provided for supervisors
and quality-controllers focused on field monitoring, verification visits, and census procedures.

ACTwatch Group et al. Malar J (2017) 16:170

Analysis

All data cleaning and analysis was completed using Stata
13.1 (©StataCorp, College Station, TX). Sampling weights
were applied to account for variations in probability of
selection, and standard error estimation accounted for
clustering at the ward/village track level.
Standard ACTwatch indicator definitions have been
reported elsewhere [5, 6, 8]. Briefly, anti-malarials identified during the outlet drug audit were classified according
to information on drug formulation, active ingredients
and strengths. Artemisinin monotherapies were further classified as oral and non-oral, the latter including
medicines recommended for the first-line treatment of
severe malaria. Anti-malarial market composition was
defined as the proportion of outlets of each type, or the
proportion of outlets within each domain, among outlets
with oral AMT in stock on the day of the survey. Market share, or the relative distribution of the anti-malarials
to individual consumers recorded in the drug audit, was
standardized to allow meaningful comparisons between
anti-malarials with different treatment courses and different formulations. The adult equivalent treatment dose
(AETD) was defined as the amount of active ingredient
required to treat an adult weighing 60 kg according to
WHO treatment guidelines [1]. Provider reports on the
amount of the drug sold or distributed during the week
preceding the survey were used to calculate volumes
according to type of anti-malarial. The volume of each
drug was calculated as the number of AETDs that were
reported to have been sold/distributed during the week
preceding the survey. Measures of volume included all
dosage forms to provide a complete assessment of antimalarial market share.
The price of oral AMT is reported as the median price
per 50 mg tablet of oral AMT sold. This is a departure
from the standard ACTwatch method of calculating
price, which is the median price per one adult equivalent treatment dose (AETD). Price was calculated in this
manner to provide a more relevant price of oral AMT,
given that most commonly this monotherapy is sold as
one or two tablets, rather than a full course treatment of
20 tablets. The type of outlets supplying oral AMT to service delivery points was calculated as the percentage of
outlets reportedly named by the provider as the distributor of the oral AMT product. Providers had the option to
name more than one supplier/source.
Protection of human subjects

The 2015 outlet survey protocol received ethical approval
from PSI’s Research Ethics Board, headquartered in
Washington DC, USA and registered under the Office
of Human Research Protections (OHRP FWA00009154,
IRB#00006961).
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Results
Availability

Table 1 shows a detailed breakdown of oral AMT availability at the outlet level across domains. A total of 3859
outlets across all four geographic domains had an antimalarial in stock on the day of survey. Of these, 988 outlets had oral AMT in stock on the day of the survey, and
217 had oral AMT within the past 3 months.
The national estimate for oral AMT availability on
the day of the survey among anti-malarial stocking outlets was 17.3%. Observing domain differences, availability was highest among outlets in the Western border at
36.8% versus the Eastern domain (15.0%), Central domain
(19.3%), and Coastal domain (10.7%). The percentage
of outlets stocking oral AMT in the past 3 months but
not on the day of the survey was 2.9% nationally and was
comparable across domains.
Figures 1 and 2 illustrate the relative distribution of
service delivery points for oral AMT stocking outlets, by
domain and by outlet type. Figure 1 shows that in terms
of absolute number of places where oral AMT medicines
were available, most were categorized as private sector
outlets. Over 90% of the oral AMT service delivery points
comprised of private sector outlets: general retailers
(49.4%), pharmacies (23.5%), and itinerant drug vendors
(14.2%). The relative distribution of oral AMT-stocking
outlets by outlet type was less than 10% for community
health workers and private for-profit facilities (6.9 and
6.1%, respectively). Of the 988 oral AMT-stocking outlets
nationally, the Eastern area had the largest relative number of oral AMT-stocking outlets nationally at 35.3%, followed by the Central area (32.7%). The relative number
of oral AMT-stocking outlets was 23.0% in the Coastal
domain and less than 10% in the Western domain (Fig. 2).
Table 2 shows a breakdown of audited oral AMT products. Of the 1036 oral AMT products audited (Eastern,
N = 308; Central, N = 166, Coastal, N = 180, Western,
N = 648), tablet formulation was either artemether
(68 products) or artesunate (968 products). The most
commonly audited oral AMT product was branded as
Artesunate®, manufactured by Mediplantex in Vietnam
(n = 834). Other common products included Artem®
by Kunming Pharmaceutical Corporation in China
(n = 26) and AA-Artemether® by AA medical products in Vietnam (n = 22). All artesunate tablet products with known product information had a strength
of 50 mg (n = 929) whereas artemether tablets with
known product information were found in strengths of
40 mg (n = 33) and 50 mg (n = 24). All branded oral
AMT products came in a pack size of 12 tablets with
the exception of Artesunate® manufactured by Myanmar Pharmaceutical Factory or Tatmadaw Pharmaceutical Factory in Myanmar that were found in tins of 100

16.4
1.4
15.0

Oral AMT in stock or in the past 3 months

Oral AMT on the day of the survey

(10.8, 20.5)

(0.9, 2.1)

(12.0, 22.1)
19.3

3.1

22.4

594
%

95% CI

1330
%

N

N

Oral AMT in the past 3 months, not on the day of the survey

Proportion of anti-malarial-stocking outlets stocking

Stocking an anti-malarial

Number of outlets in sample

Central

Eastern

Table 1 Availability of oral artemisinin monotherapy by domain

(15.5, 23.7)

(1.7, 5.9)

(18.3, 27.2)

95% CI

36.8

4.7

41.5

%

1065

N

Western

(32.1, 41.6)

(3.4, 6.6)

(36.2, 47.0)

95% CI

10.7

4.7

15.5

%

870

N

Coastal

(8.2, 14.0)

(3.0, 7.5)

(12.2, 19.4)

95% CI

17.3

2.9

20.3

%

3859

N

Total

(14.8, 19.8)

(1.9, 3.9)

(17.6, 23.0)

95% CI
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N=988

Community health worker
Private for profit health facility
Pharmacy
General retailer
Itinerant drug vendor

Fig. 1 Market compostion of oral AMT-stocking outlets, by outlet
type

N=988

Eastern
Central
Western
Coastal

Fig. 2 Distribution of oral AMT stocking outlets, by domain
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tablets (n = 14). There were 50 oral AMT products that
were found as loose tablets stored in containers (plastic tins) without product information (brand, manufacturer, and country of manufacturer), represented by two
dashes in the table.
The characteristics of oral AMT supply and demand
are shown in Table 3. According to provider reporting,
most oral AMT products were obtained from a pharmacy
(53.5%) or a fixed-location medicine wholesale outlet
(40.0%). Only 8.1% of oral AMT products were obtained
from some other type of supplier; the most common
other types of suppliers cited were mobile distributor, village buyer, rural health centre, or ‘floating shops’ which
were reportedly found on boats that traverse local rivers. Over half (53.1%) of oral AMT products had been
obtained from a supplier within the past 3 months. The
median number of packages in stock on the day of the
survey was 1.0 (IQR = 0.4–2.4). Over two-thirds (68.2%)
of oral AMT products were reportedly requested by
name by consumers.
Table 4 displays the breakdown of oral AMT product characteristics. Of the 1036 oral AMT products in
stock on the day of the survey, 75.0% was Artesunate®,
manufactured by Mediplantex in Vietnam. Another 8.0%
of oral AMT products were manufactured by AA medical products in Vietnam and were either AA-Artesunat® (n = 17) or AA-Artemether® (n = 22). Kunming

Table 2 Product catalogue of the types and number of oral AMT products
Country of manufacturer

Manufacturer

Brand name

Strength (mg)

Package size

China

Kunming Pharmaceutical Corporation (KPC)

Artem

40

12

Chongqing Holley Pharmaceutical Co. Ltd.

Artemether

40

12

7

Vietnam

AA medical products

AA-Artemether

50

12

22

Artemether tablets

N
68
26

–

–

Artemether

50

12

2

–

–

Artemether

–

–

11

Guilin Pharmaceutical Co. Ltd.

50

12

2

Jiangxi Xierkangtai Pharmaceutical Co. Ltd.

50

12

1

Artesunate tablets
China

968

Zhangfeng Pharmaceutical Factory
Zhejiang Holley Nanhu Pharmaceutical Co. Ltd.

50

12

17

Arthesis 50 mg

50

12

12

50

100

14

50

12

17

Myanmar

Myanmar/Tatmadaw Pharmaceutical Factory

Vietnam

AA medical products

AA-Artesunat

Central Pharmaceutical Factory No. 1

Artesunate

Mediplantex

50

12

2

50

12

834

Medopharm

50

12

2

Mekophar Chemical Products

50

12

1

Traphaco

Traphasunat 50 mg

50

12

9

–

–

Artesunate

50

12

18

–

–

Artesunate

–

–

Total oral AMT

39
1036
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National
%
Proportion of oral AMT products that were
reportedly obtained from

(95% CI)

N = 1335

Pharmacy

53.5

(47.3, 59.7)

Fixed-location medicine wholesale outlet

40.0

(33.5, 46.6)

Other (mobile distributor, village buyer, rural
health centres, and ‘floating shops’)

8.1

(5.3, 10.9)

Proportion of oral AMT products that were
reportedly obtained from a supplier within
the past 3 months

53.1

(47.1, 59.0)

Median [IQR](N)
Among oral AMT products, median
Number of oral AMT packages in stock on the
day of the survey

1.0

[0.4–2.4](1302)

%

(95% CI)

68.2

(63.0, 73.4)

Proportion of oral AMT products* that
Were reportedly requested by name by
consumers

*Oral AMT products in stock on the day of the survey or reportedly in stock in
the past three months

Table 4 Characteristics of oral AMT products: expiry, manufacturer, and price
%

(95% CI)

Proportion of oral AMT products
Expiry datesΨ
  Expired at the time of the survey
  Less than 1 year to expiry

N = 912
14.7

(9.8, 19.7)

23.6

(18.3, 29.0)

  1–2 years to expiry

9.7

(5.7, 13.8)

  Greater than 2 years to expiry

60.4

(54.2, 66.6)

Manufacturer

N = 1036

  Mediplantex (Vietnam)

75.0

(68.9, 81.1)

  AA medical products (Vietnam)

8.0

(4.7, 11.2)

  Kunming Pharmaceutical Corporation
(China)

2.6

(1.0, 4.2)

  Other

14.4

(10.1, 18.7)

Median [IQR](N)
Among oral AMT products, median
Retail price per 50 mg tablet sold to
patients

$0.16

[0.12–0.18](989)

Retail percentage mark-up

30.1%

[14.9–54.2%](817)

Number of 50 mg tablets typically dispensed to treat malaria in an adult

2

[1.2–7.2](928)

Ψ There were 124 oral AMT products missing expiry date information; these
were not included in thedenominator

At the time of the survey, of the 912 oral AMT products with known expiry dates, 14.7% of oral AMT products audited were expired and slightly less than a quarter
(23.6%) had less than a year to expiry. Over 60% of oral
AMT products found at the time of the survey still had
a shelf life of greater than 2 years. When broken down
by manufacturer, 72.5% of Artesunate® by Mediplantex
had a shelf life of greater than 2 years. Over 85% of products manufactured by AA Medical were expired or due
to expire within the year, and almost 85% of oral AMT
that had been manufactured in China was expired at the
time of the survey. The median number of oral AMT tablets typically dispensed to treat malaria in an adult was
two tablets, approximately 10% of an AETD, and had an
IQR of 1.2–7.2 tablets. The median price of a 50 mg tablet after the median 30.1% retail percentage mark-up was
$0.16. This equated to a treatment price of $0.32 for a
typical oral AMT treatment dose.
Figure 3 shows the national level anti-malarial market
share for each type of anti-malarial distributed: ACT,
chloroquine, other non-artemisinin therapies, and nonoral and oral artemisinin monotherapies. Figure 4 illustrates the oral AMT market share for artemether and
artesunate and for major brand names. Sale or distribution of oral AMT comprised 14.8% of the anti-malarial
market nationally in 2015. Of all oral AMT sold or distributed, 79.9% was labelled A
 rtesunate® and manufactured by Mediplantex in Vietnam. Other products that
were sold in low volumes included Artesunate® by Central Pharmaceutical Company in Vietnam, and Artem® by
Kunming Pharmaceutical Corporation in China. Around
5% of the oral AMT products had unknown brand and
manufacturing information.

100
90

PERCENT MARKET VOLUME

Table 3 Characteristics of oral AMT supply and demand

80
70
60
50
40
30
20
10
0

Pharmaceutical Corporation in China was responsible
for manufacturing 2.6% of oral AMT products (all were
Artem®) found in Myanmar in 2015.

Any ACT

Chloroquine
Non-Oral AMT

Other Non-artemisinin
Oral AMT

Fig. 3 National market share of different classes of anti-malarials
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100
90
80
70
60
50
40
30
20
10
0
Unknown product info
Artemether brands
Other Artesunate brands
ARTESUNATE by Central Pharma
ARTESUNATE by Mediplantex

Fig. 4 Market share by oral AMT product type

Discussion
This study provided timely, actionable evidence to
address persistent sale and distribution of oral AMT in
Myanmar. The results of the study illustrate widespread
availability and distribution of oral AMT across Myanmar. Strategies to confiscate this medicine from the marketplace, and to scale-up existing efforts to completely
remove this monotherapy are urgently needed. Lessons
learnt from other countries can be applied to ensure successful strategies, though must be adapted to meet Myanmar’s ethnically diverse and vastly different geographical
landscape.
Where is oral artemisinin monotherapy available?

Findings from the 2015 ACTwatch outlet survey found
a high number of oral artemisinin monotherapies, with
over 1000 audited products representing over 10% of
all anti-malarial medicines audited. The findings illustrate how the private sector remains responsible for the
majority of oral AMT distribution in Myanmar. General
retailers, pharmacies, and itinerant drug vendors were
the outlet types most commonly responsible for stocking oral AMT. This is consistent with 2015 market share
observations that show oral AMT market share was
markedly higher in the total private sector (19.6%) versus community health workers (3.8%) [9]. Future strategies to address the removal of this medicine must target
and engage with the private sector, including pharmacies,
general retailers and itinerant drug vendors.
At the national level, one in five anti-malarial-stocking outlets had oral AMT in stock. Close to half of antimalarial-stocking private sector outlets in the Western
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domain were stocking oral AMT, pointing to widespread
availability in areas next to the Indian border. Although
the oral-AMT availability was highest in the Western
domain, the majority of oral AMT-stocking outlets were
located in the more populous Eastern and Central areas
of the country. Oral AMT availability across the country is of grave concern given Myanmar is considered an
important probable origin and route of spread of multidrug resistance to other parts of the world.
The results are somewhat surprising in Eastern Myanmar, given that several strategies have been implemented
in this area since 2012 to contain the spread of artemisinin drug resistance [10]. One of the key strategies
has been a project to remove oral AMT from the private
sector and replace it with quality-assured ACT through
the AMTR project. In 2012 the main distributor of oral
AMT, AA Pharmaceuticals, was identified and engaged
in an agreement to replace sales of oral AMT with firstline, subsidized ACT. Additional strategies included
behaviour change communication (BCC) to increase
demand for ACT, coupled with intensive pharmaceutical
detailing operations, targeting general retailers, pharmacies and itinerant drug vendors through product promoters to facilitate ACT uptake in the supply chain. These
efforts were coupled by the significant role of the Myanmar FDA, which has played an important role in trying to
enforce the ban on oral AMT registration and importation despite limited resources and challenges in gaining
access to border control areas. This included high-level
advocacy with the military-operated Tatmadaw Pharmaceutical to halt the manufacturing of oral AMT in the
country in late 2015. It is expected that the last batch of
oral AMT manufactured by Tatmadaw was produced in
late 2015 as an agreement was drawn up between the
Ministry of Health (MoH) and the Ministry of Defense.
Indeed, this locally manufactured product was rarely
audited in the survey.
Despite these efforts by the government and international NGOs, market trend data from the Eastern part
of Myanmar showed that while availability of oral AMT
has declined over the years, between 2014 and the current study round, an increase in availability was observed
among general retailers, pharmacies and itinerant drug
vendors from 10.3% in 2014 to 27.2%. That said, availability of oral AMT was lowest in the Eastern domain
as compared to other domains, pointing to the success
of the many strategies. It is postulated that in 2015 there
may have been a final push by distributors to get rid of
any last remaining stock of oral AMT, before it expired.
Perhaps more likely, this could reflect a 3–4 month stockout of ACT medicines during the peak malaria transmission season in 2015. Frequent changes in key leadership
positions within the Ministry of Health resulted in an
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unexpected delay in obtaining approval to import ACT
medicines into the country for the AMTR project, indicating the importance of constant supply of ACT to
ensure universal coverage and reduce the distribution of
unwanted medicines.
Other higher level, multi-pronged strategies may be
considered that speak to enforcement and regulation
of the ban. Strategies have recently been implemented
in Cambodia resulting in the successful removal of
oral AMT from the private sector [11]. These included
increasing private sector access to subsidized first-line
ACT. To enforce the ban on oral AMT instituted in
2008, strategies have included the recruitment of officials
known as the ‘Justice Police’, as well as training of over
400 police to identify oral AMT at service delivery points
and actively enforce the ban by removing products and
sanctioning outlets. The government also used mystery
clients to further identify outlets selling any oral AMT,
and instituted a system of licensing drug outlets and
using the Justice Police to regularly check for and confiscate fake, substandard or banned drugs. In addition, an
international collaboration led by INTERPOL succeeded
in interrupting one trade route of a major Chinese producer of fake artemisinin that had flooded the market in
Cambodia [12]. These efforts were supported by a communication campaign to educate private providers and
consumers about the dangers of oral AMT. Similar success stories have also been observed in the Lao Peoples
Democratic Republic, where the availability of oral AMT
significantly decreased from 22.9% in southern Laos in
2003 to 4.8% in 2012 [13]. This was attributed to several
strategies to improve case management in the private
sector, but also reflected changes to treatment policy,
trading agreements with manufacturers of oral AMT, and
amendments to the law on Drugs and Medical Products
to ensure adequate registration, distribution, and supply
of all medicines.
Such strategies may be applicable in Myanmar to
ensure effective and immediate removal of oral AMT
from the marketplace. To-date, there has been no official communication on oral AMT in Myanmar, including a lack of communication on banned products and
the dangers of continuing use of such products. Communication campaigns could be an important first step to
tackle the widespread availability of oral AMT. However,
these interventions must be couched with the reality that
Myanmar has over 100 ethnic groups, with many different languages, which can pose a challenge for clear and
effective communication. Future strategies must also consider that many areas of Myanmar are under conflict and
controlled by ethnic armed groups, for which the central
government and local and international NGOs have variable access. The political and geographical diversity must
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be considered and overcome to ensure effective implementation and successful behaviour change strategies.
Promisingly, the Myanmar FDA underwent a major
restructuring of their department in 2014 and the
Government of Myanmar has allocated considerable
resources to improve the infrastructure, including an
expansion of human resources. In addition to the Central
level, the FDA now has officers at the State and Division
level, allowing for greater national influence. This presents an opportunity for implementers to work closely
with the FDA as a means to strengthen and regulate the
sale of oral AMT and educate wholesale providers about
the dangers of oral AMT.
What types of products are found on the shelf and being
distributed?

All oral AMT products found in Myanmar were manufactured in either Vietnam, China, or locally in Myanmar, with the vast majority having been manufactured
in Vietnam. Three-quarters of the available products
were Artesunate®, manufactured by Mediplantex in
Vietnam. This was also the most commonly distributed
product by far, capturing over 80% of the market share.
These products were stamped with ‘GMP-WHO’ (Good
Manufacturing Practices-World Health Organization),
misleadingly indicating to both patients and providers
that these drugs are recommended by the WHO based
on the implicit level of quality conferred by the manufacturer’s GMP status. This is of further concern given that
‘GMP-WHO’ is a fake label and does not exist as a quality
standard. Additionally, the instructions were only in Chinese and English—with no Myanmar translation—and
also included vague contraindications, such as ‘pregnant
women should use the drug carefully’.
With many products having a shelf life of greater than
2 years at the time of the survey, and some products with
an import registration number, this confirms that there
has been both recent manufacturing of the product as
well as recent importation. Indeed, direct communication with the manufacturer confirmed that oral AMT
was still in production in late 2016, with two strengths
(50 and 100 mg), with a minimum order of 20,000 tablets
[14].
The findings from the product audit speak to three
important conclusions regarding importation and future
strategies to remove the medicine. First, the recent
import of this medicine confirms that there are significant gaps or loopholes in the regulatory policy surrounding oral AMT, either that the ban on import is not
being enforced, or simply that the import of oral AMT
products with a registration license is still legal in Myanmar. Myanmar can potentially expect further import
of this medicine until the manufacturer decides to stop
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producing it. Second, as no other single brand had more
than three percent of the market share, another key conclusion from this study is that currently a single product
and manufacturer dominates the market. This provides
an opportunity, not dissimilar from that of the situation
with a key supplier identified in the Eastern part of the
country several years ago [10], to target the top of the
supply chain and halt further large-scale distribution
of this product. Finally, while oral AMT manufacturers were limited to three countries, the wider range of
brand names and one-off products, seems to suggest that
oral AMT is not only being imported under official supply chains (e.g. products with registration numbers) but
through unofficial channels across the border. Increased
regulation of borders or licensing of medicines will be
necessary to ensure that removal of oral AMT is sustained, which could be addressed nationally by explicit
communication from the FDA to wholesalers regarding
the dangers of oral AMT. This should also be addressed
by WHO as part of their policy to halt the manufacturing
of oral AMT. On a yearly basis, WHO routinely reaches
out to manufacturers of oral AMT and asks them to sign
agreements to stop production of this medicine [4].
What are the provider practices regarding the re‑supply
and sale of oral artemisinin monotherapy?

Oral AMT was reportedly obtained by providers from a
limited number of supplier types. Pharmacies and fixedlocation medicine wholesale outlets were the supplier
for 93.0% of available products. Most outlets had a small
number of oral AMT packages in stock and reported
fairly frequent re-stocking with small volume purchases.
The limited number of supplier types and minimal
amount of oral AMT products in stock at the lowest level
suggests that the oral AMT supply chain could be rapidly
disrupted. This would additionally benefit from several
strategies mentioned previously to ensure tightened regulation of the policy.
As providers typically had only one or two packages
in stock, it is perhaps not a surprise that oral AMT was
most often distributed in doses of approximately two
tablets, making it feasible for a provider to treat up to six
patients with a 12-tablet package. Sub-optimal dosing of
oral AMT medicines is particularly rampant throughout
the private sector. This is not only unsafe for the patient,
but also dangerous over time as the selection pressure
on parasites to develop resistance to artemisinin is quite
high [15]. Evidence of artemisinin-resistance is now
prevalent throughout much of Myanmar where malaria
is endemic and the spread of molecular markers across
Myanmar has now been detected on the border with
India [16]. Continued distribution of oral AMT at such
a low dosage will further exacerbate the prevalence of
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artemisinin resistant malaria parasites in Myanmar and
increase the likelihood of spread of artemisinin resistance
into China, India, and westward [17].
More than two-thirds of oral AMT products were
reportedly requested by name by patients, suggesting
that consumer demand may also play a role. A recent
study that investigated factors associated with outlet providers who stock oral AMT in Myanmar, found that the
odds of stocking oral AMT was almost four times higher
among providers who report that customers ask for this
by name compared to providers that report costumers do
not demand the medicine by name [18]. Evidence from
other countries also supports this, where administration of the first-line treatment seems to depend on what
patients demand [19]. This points to the need for strategies that not only focus on provider behaviour change,
but also address patient preferences and awareness of
what medicine to ask for. As such, targeting provider
knowledge, preferences and behaviour alone may not be
sufficient to drive uptake of the first-line treatment [20].
To help remove oral AMT from the market, there is likely
a need for supporting interventions to drive consumer
awareness and demand for first-line treatment [21].
The policy implications from this paper are clear. The
production of oral AMT by Vietnamese manufacturers
must end. The continued manufacturing and distribution not only threatens efforts by WHO efforts to combat artemisinin resistance, but also threatens malaria
control efforts in Africa. It is both discouraging and disheartening that while oral AMT consumption is banned
in Vietnam, manufacturing and exportation is however
permitted [WWARN, pers. comm.]. These disappointing actions should act as a rallying call to the global community, especially given the financial investment and
international and national commitment to preserve the
efficacy of artemisinins and ultimately save lives. Continued production of oral AMT should be raised before
the World Health Assembly as a means to gather further
momentum by the international community to stop production of this dangerous anti-malarial.
Finally, as the sale of oral AMT is typically just two tablets, the price of a typical dose has implications for pricing quality-assured recommended alternatives. While a
private sector subsidy has reduced the price of qualityassured ACT in Myanmar, a typical dose of oral AMT
remains a less expensive option for a patient and provides a greater profit margin for the provider than firstline ACT for treatment. The wholesale to retail markup
of oral AMT was much higher than that of an ACT in
the private sector: 30.2 versus 20.0% for ACT in the context of an ACT subsidy programme [7]. Coupled with the
knowledge that oral AMT shelf life is also double that
of ACT (approximately 4 versus 2 years, respectively)
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[10], evidence suggests a number of financial incentives
for providers to stock and sell this monotherapy over
an ACT. Furthermore, the median treatment price for
a typical oral AMT treatment dose of two tablets was
$0.32. This is comparable, and is in fact more than 10%
less expensive than the median price of $0.36 for ACT in
Myanmar, suggesting that oral AMT may be more affordable to patients. Consumer price and potential profit for
providers may be factors influencing demand for oral
AMT in Myanmar, as has been identified in other settings introducing ACT in competition with cheaper antimalarial alternatives [8, 22, 23]. Increased provider and
consumer knowledge on the differing treatment guidelines between Plasmodium falciparum and Plasmodium
vivax malaria, could create market demand for appropriate treatment for each malaria species according to
national guidelines.

Limitations
The 2015 ACTwatch Outlet Survey in Myanmar was
not designed to capture the entire anti-malarial market or to map the entire supply chain for oral AMT and
for all anti-malarial medicines. The study was limited to
the private sector and community health workers—government facilities were not visited. However, it is likely
that oral AMT availability and distribution are relatively
low in government health facilities. This study used the
adult equivalent treatment dose (AETD) for the unit of
analysis in calculating relative market share for each type
of anti-malarial medicine. However, oral AMT is most
typically sold in a treatment dose of two tablets instead
of the full AETD of about 20 tablets. As such, the proportion of patients that are treated with oral AMT relative to other types of anti-malarials is likely much higher
than the market share estimated using AETDs distributed. Given the widespread availability and distribution
of oral AMT, further study is needed to understand the
supply chain at various levels. This is particularly true
at higher levels in order to understand where and under
what guise oral AMT is imported. Additional surveys in
key areas of China or along the India border would be
particularly beneficial. The study also did not assess consumer demand or behaviour directly. Further studies that
engage the patient, especially in a qualitative manner, are
also necessary to inform effective strategies to address
consumer knowledge and behaviour.
Conclusion
Given the high availability and distribution of oral AMT,
it is possible that Myanmar has become the last remaining viable market for any oral AMT in the region that is
not expired or is still being manufactured. This could be
due to loopholes in Myanmar’s regulatory policy and/or
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stringent regulations in the manufacturing country that
do not permit local sale of oral AMT. Other factors that
contribute to the uptake and ongoing distribution of this
medicine speak to the long shelf-life of the product, provider dispensing practices, price and consumer demand.
Urgent action is required to stop the manufacturing, sale
and distribution of this medicine to protect the efficacy
of ACT and curb the spread of multi-drug resistant parasites. A multi-pronged approach is needed to address
the problem. Targeting suppliers at the top of the supply chain, improving and expanding upon BCC activities for both the provider and consumer, and demand
for appropriate medicines are all crucial. International
advocacy is also urgently needed to stop the manufacturing and exportation of oral AMT in Vietnam and China,
and advocacy measures by WHO are needed to encourage manufacturers to halt production. National policy
changes that ban the full import, distribution, and sale
of oral AMT and ultimately implementation of a programme for removal of oral AMT from the market would
create a far more conducive environment for the support
of these activities.
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